Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.

ABSTRACT:

Objective

Pembrolizumab and dostarlimab are immune checkpoint inhibitors that target programmed death receptor 1 (PD-1). Combination anti-PD-1 regimens have been shown to exhibit favorable survival benefits when treating advanced endometrial cancer (EC). Which treatment was preferable will need to be confirmed by a cost-effectiveness comparison between them.

Methods

Based on patient and clinical parameters from RUBY and NRG-GY018 phase III randomized controlled trials, the Markov model with a 20-year time horizon was established to evaluate the cost-effectiveness of dostarlimab plus chemotherapy (DC), pembrolizumab plus chemotherapy (PC), and chemotherapy alone (C) treatment for patients with mismatch repair-proficient microsatellite-stable (pMMR-MSS) and mismatch repair-def

SUBMITTER: Zhu Y 

PROVIDER: S-EPMC11790985 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature